Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Eylea

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
PURPOSE To investigate the effect of age on aflibercept (Eylea) response in macular edema secondary to treatment-naive diabetic… Expand
2019
2019
Purpose: Aflibercept (Eylea™, Regeneron) is supplied in single-use glass vials along with 1 cc polycarbonate syringes. We sought… Expand
2019
2019
Originally approved in 2011, aflibercept is a vascular endothelial growth factor (VEGF) inhibitor. 
2018
2018
Vascular endothelial growth factor (VEGF) is a key mediator in the development and progression of choroidal neovascularization… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2017
2017
PurposeTo investigate the short-term effect of single intravitreal aflibercept injection on retrobulbar blood flow in patients… Expand
  • table 1
  • table 2
2017
2017
INTRODUCTION Pathological formation of blood vessels plays a key role in the growth and metastasis of tumors and also in several… Expand
  • figure 1
  • figure 2
2016
2016
PURPOSE We determined the intraocular pharmacokinetic properties of intravitreally injected aflibercept (Eylea) in a rabbit model… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
2016
2016
Background: We present an interesting case of bilateral retinitis pigmentosa (RP)-associated cystoid macular oedema that… Expand
  • figure 1
  • figure 2
  • figure 3
2016
2016
Anti-VEGF Drugs Anti-VEGF drugs are used to treat retinal conditions such as the wet form of age-related macular degeneration… Expand
2014
2014
Purpose OPT‐302 is a soluble receptor that specifically and potently blocks VEGF‐C and VEGF‐D activity which are involved in the… Expand